CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade CSPC Pharmaceutical Group Limited - 1093 CFD

6.00
1.64%
Market Trading Hours* (UTC) Opens on Monday at 01:30

Mon - Thu: 01:30 - 04:00 05:00 - 08:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.30
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.023325 %
Charges from full value of position ($-4.43)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.023325%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.001407 %
Charges from full value of position ($0.27)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.001407%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency HKD
Margin 5%
Stock exchange Hong Kong
Commission on trade 0%

*Information provided by Capital.com

CSPC Pharmaceutical Group Ltd ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 6.1
Open* 6.05
1-Year Change* -19.87%
Day's Range* 6 - 6.1
52 wk Range 5.20-9.56
Average Volume (10 days) 49.13M
Average Volume (3 months) 1.06B
Market Cap 72.49B
P/E Ratio 10.95
Shares Outstanding 11.90B
Revenue 34.14B
EPS 0.56
Dividend (Yield %) 4.10509
Beta 0.55
Next Earnings Date Mar 20, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 28, 2024 6.00 -0.10 -1.64% 6.10 6.15 6.00
Mar 27, 2024 6.10 0.00 0.00% 6.10 6.20 6.05
Mar 26, 2024 6.15 -0.20 -3.15% 6.35 6.40 6.05
Mar 25, 2024 6.15 -0.10 -1.60% 6.25 6.40 6.15
Mar 22, 2024 6.25 -0.05 -0.79% 6.30 6.50 6.20
Mar 21, 2024 6.35 0.05 0.79% 6.30 6.40 6.15
Mar 20, 2024 6.25 0.00 0.00% 6.25 6.35 6.20
Mar 19, 2024 6.25 -0.10 -1.57% 6.35 6.35 6.20
Mar 18, 2024 6.35 -0.15 -2.31% 6.50 6.50 6.35
Mar 15, 2024 6.50 0.15 2.36% 6.35 6.55 6.35
Mar 14, 2024 6.40 -0.10 -1.54% 6.50 6.65 6.30
Mar 13, 2024 6.30 0.20 3.28% 6.10 6.35 6.10
Mar 12, 2024 6.20 0.30 5.08% 5.90 6.20 5.85
Mar 11, 2024 5.85 0.10 1.74% 5.75 5.85 5.75
Mar 8, 2024 5.80 0.10 1.75% 5.70 5.85 5.70
Mar 7, 2024 5.70 0.00 0.00% 5.70 5.75 5.65
Mar 6, 2024 5.70 0.05 0.88% 5.65 5.80 5.55
Mar 5, 2024 5.60 -0.20 -3.45% 5.80 5.80 5.60
Mar 4, 2024 5.80 -0.15 -2.52% 5.95 6.00 5.80
Mar 1, 2024 5.95 0.00 0.00% 5.95 5.95 5.80

CSPC Pharmaceutical Group Limited Events

Time (UTC) Country Event
Thursday, May 23, 2024

Time (UTC)

10:59

Country

CN

Event

Q1 2024 CSPC Pharmaceutical Group Ltd Earnings Release
Q1 2024 CSPC Pharmaceutical Group Ltd Earnings Release

Forecast

-

Previous

-
Thursday, May 30, 2024

Time (UTC)

02:00

Country

CN

Event

CSPC Pharmaceutical Group Ltd Annual Shareholders Meeting
CSPC Pharmaceutical Group Ltd Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 30936.9 27866.9 24942.2 22103.2 17716.5
Revenue 30936.9 27866.9 24942.2 22103.2 17716.5
Cost of Revenue, Total 8680.49 6731.78 6256.88 6192.21 5979.19
Gross Profit 22256.4 21135.1 18685.3 15911 11737.4
Total Operating Expense 23314.4 21034.6 18552.5 17503 13893.6
Selling/General/Admin. Expenses, Total 11484.5 11457.3 10361.5 9460.59 6841.1
Research & Development 3986.52 3432.59 2889.84 2000.43 1342.1
Interest Expense (Income) - Net Operating -461.56 -352.319 -506.452 -83.303 -112.822
Unusual Expense (Income) 31.401 23.421 -320.669 132.396 16.02
Other Operating Expenses, Total -407.021 -258.231 -128.57 -199.311 -172.01
Operating Income 7622.55 6832.32 6389.72 4600.18 3822.96
Interest Income (Expense), Net Non-Operating -40.286 14.779 1.3 25.981 -30.783
Net Income Before Taxes 7582.26 6847.1 6391.02 4626.16 3792.18
Net Income After Taxes 6232.05 5688.12 5229.01 3733.35 3058.42
Minority Interest -140.66 -82.939 -69.355 -19.246 22.383
Net Income Before Extra. Items 6091.39 5605.19 5159.65 3714.11 3080.8
Net Income 6091.39 5605.19 5159.65 3714.11 3080.8
Income Available to Common Excl. Extra. Items 6091.39 5605.19 5159.65 3714.11 3080.8
Income Available to Common Incl. Extra. Items 6091.39 5605.19 5159.65 3714.11 3080.8
Diluted Net Income 6091.39 5605.19 5159.65 3714.11 3080.8
Diluted Weighted Average Shares 11918.5 11953.8 11955.5 11956.8 11984.8
Diluted EPS Excluding Extraordinary Items 0.51109 0.4689 0.43157 0.31063 0.25706
Dividends per Share - Common Stock Primary Issue 0.18547 0.14667 0.10732 0.0931 0.08231
Diluted Normalized EPS 0.51325 0.47053 0.40963 0.31956 0.25814
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 8027.14 8053.27 7441.39 7885.49 7736.13
Revenue 8027.14 8053.27 7441.39 7885.49 7736.13
Cost of Revenue, Total 2308.1 2534.67 2267.28 2141.67 2208.61
Gross Profit 5719.04 5518.6 5174.11 5743.82 5527.52
Total Operating Expense 6118.49 6251.14 5435.82 5996.87 5768.24
Selling/General/Admin. Expenses, Total 2687.35 2750.68 2522.28 3013 2890.8
Research & Development 1295.96 1007.65 1066.27 1036.17 982.56
Interest Expense (Income) - Net Operating -168.775 50.09 -216.558 -61.47 -230.044
Unusual Expense (Income) 23.659 -16.485 0.299 0
Other Operating Expenses, Total -27.809 -91.947 -186.96 -132.81 -83.681
Operating Income 1908.65 1802.13 2005.56 1888.63 1967.89
Interest Income (Expense), Net Non-Operating -8.059 -21.166 -20.369 -11.018 -12.351
Net Income Before Taxes 1900.59 1780.96 1985.19 1877.61 1955.54
Net Income After Taxes 1588.94 1469.1 1661.1 1543.86 1592.79
Minority Interest -50.796 -40.257 -37.552 -42.23 -31.106
Net Income Before Extra. Items 1538.14 1428.84 1623.55 1501.63 1561.69
Net Income 1538.14 1428.84 1623.55 1501.63 1561.69
Income Available to Common Excl. Extra. Items 1538.14 1428.84 1623.55 1501.63 1561.69
Income Available to Common Incl. Extra. Items 1538.14 1428.84 1623.55 1501.63 1561.69
Diluted Net Income 1538.14 1428.84 1623.55 1501.63 1561.69
Diluted Weighted Average Shares 11869.6 11917 11919.3 11918.7 11918.7
Diluted EPS Excluding Extraordinary Items 0.12959 0.1199 0.13621 0.12599 0.13103
Dividends per Share - Common Stock Primary Issue 0.12955 0 0.09715 0 0.08537
Diluted Normalized EPS 0.13125 0.1199 0.13506 0.12601 0.13103
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 23957.2 20336.5 15921.4 13697 13803.5
Cash and Short Term Investments 13795.7 10727.1 8794.67 5956.93 6628.42
Cash 8000.85 9283.64 7259.46 4118.24 4335.61
Short Term Investments 5794.86 1443.41 1535.21 1838.69 2292.81
Total Receivables, Net 6836.21 6548.65 4744.78 4450.74 3629.18
Accounts Receivable - Trade, Net 4104.5 3409.28 2543.12 2399.03 2128.37
Total Inventory 2554.86 2480.37 1861.07 2535.74 3045.32
Prepaid Expenses
Other Current Assets, Total 770.379 580.425 520.86 753.545 500.566
Total Assets 41769.8 34741.6 30070.2 26318.3 23216.8
Property/Plant/Equipment, Total - Net 10976.9 9563.92 8934.34 9282.38 6692.22
Property/Plant/Equipment, Total - Gross 15596.2 13426.6 12177.1 12572.5 9495.94
Accumulated Depreciation, Total -4619.31 -3862.7 -3242.73 -3290.1 -2803.72
Goodwill, Net 234.904 149.983 149.983 188.964 140.752
Intangibles, Net 1908.11 467.854 508.742 1135.66 806.986
Long Term Investments 3783.08 3356.49 3175.62 1485.71 898.542
Other Long Term Assets, Total 909.596 612.871 622.827 378.223 874.849
Total Current Liabilities 8958 7226.04 6301.84 6236.77 7247.02
Accounts Payable 1703.49 1481.36 1204.57 1110.88 1619.36
Accrued Expenses 728.165 519.256 385.881 371.337 445.834
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 295.555 38.424 223.835 97.235 70.589
Other Current Liabilities, Total 6230.79 5187 4487.56 4657.32 5111.24
Total Liabilities 11572.2 8754.9 7737.92 7856.6 8164.58
Total Long Term Debt 286.989 55.62 92.879 90.3 0
Long Term Debt 28.95 0
Deferred Income Tax 611.993 381.484 320.444 304.427 237.917
Minority Interest 1444.34 841.559 768.785 1056.44 477.34
Other Liabilities, Total 270.917 250.198 253.968 168.656 202.303
Total Equity 30197.5 25986.7 22332.3 18461.7 15052.3
Common Stock 10899.4 10899.4 10899.4 10899.4 10899.4
Additional Paid-In Capital 196.574 46.794 46.794 46.794 46.794
Retained Earnings (Accumulated Deficit) 19163.2 15154.5 11523 7406 4055.03
Other Equity, Total 22.047 -28.446 -36.246 -26.906 -2.403
Total Liabilities & Shareholders’ Equity 41769.8 34741.6 30070.2 26318.3 23216.8
Total Common Shares Outstanding 11933.2 11950 11973.8 11973.8 11973.8
Unrealized Gain (Loss) 237.134 53.423
Capital Lease Obligations 258.039 55.62 92.879 90.3 0
Treasury Stock - Common -83.71 -85.6 -100.706 -100.706 0
Note Receivable - Long Term 0 253.953 757.331 150.432
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total Current Assets 24381.6 23957.2 22828.5
Cash and Short Term Investments 12090.7 13872.9 13408.8
Cash 10298 9064.22
Short Term Investments 1625.43 3574.86 4344.54
Total Receivables, Net 8879.42 6836.21 6229.46
Accounts Receivable - Trade, Net 5748.08 4104.5 4009.2
Total Inventory 2751.95 2554.86 2624.3
Other Current Assets, Total 659.499 693.224 565.944
Total Assets 43673.2 41769.8 38838.5
Property/Plant/Equipment, Total - Net 11358.6 10976.9 10078.4
Goodwill, Net 234.904 234.904 221.591
Intangibles, Net 2264.52 1908.11 1464.22
Long Term Investments 4719.03 3783.08 3084.78
Note Receivable - Long Term 0 269.365
Other Long Term Assets, Total 714.633 909.596 891.66
Total Current Liabilities 9025.67 8958 8459.25
Accounts Payable 2028.8 1703.49 1675.36
Accrued Expenses 728.165
Notes Payable/Short Term Debt 0 0 0
Current Port. of LT Debt/Capital Leases 208.477 295.555 477.111
Other Current Liabilities, Total 6788.4 6230.79 6306.78
Total Liabilities 11853.8 11572.2 10797.2
Total Long Term Debt 206.785 286.989 205.449
Capital Lease Obligations 186.885 258.039 193.659
Deferred Income Tax 556.576 611.993 516.071
Minority Interest 1692.41 1444.34 1373.84
Other Liabilities, Total 372.317 270.917 242.602
Total Equity 31819.5 30197.5 28041.3
Common Stock 10899.4 10899.4 10899.4
Additional Paid-In Capital 290.825 196.574 110.38
Retained Earnings (Accumulated Deficit) 20934.8 19163.2 17099.2
Treasury Stock - Common -334.67 -83.71 -83.71
ESOP Debt Guarantee
Other Equity, Total 29.124 22.047 15.989
Total Liabilities & Shareholders’ Equity 43673.2 41769.8 38838.5
Total Common Shares Outstanding 11903.2 11933.2 11933.2
Property/Plant/Equipment, Total - Gross 15009.1 14201.4 13039.5
Accumulated Depreciation, Total -4971.83 -4619.31 -4229.35
Long Term Debt 19.9 28.95 11.79
Cash & Equivalents 10465.3
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line 7582.26 6847.1 6391.02 4626.16 3792.18
Cash From Operating Activities 7627.06 4636.63 6739.61 3783.9 3795.29
Cash From Operating Activities 955.461 838.391 791.967 673.641 594.006
Amortization 90.352 25.361 15.121 17.954 20.142
Non-Cash Items -464.546 -545.12 -1077.66 -149.795 -131.162
Cash Taxes Paid 1334.58 1141.18 1061.02 866.825 636.074
Cash Interest Paid 13.451 7.105 10.322 32.426 74.337
Changes in Working Capital -536.464 -2529.1 619.16 -1384.06 -479.872
Cash From Investing Activities -6795.98 -637.326 -2129.51 -2457.19 -3627.87
Capital Expenditures -2722.69 -1758.45 -1576.61 -2122.67 -2156.86
Other Investing Cash Flow Items, Total -4073.29 1121.12 -552.907 -334.521 -1471.01
Cash From Financing Activities -1904.07 -2196.61 -1470.98 -1545.54 -151.387
Financing Cash Flow Items 342.338 -20.164 -19.961 -1590.8 1497.52
Total Cash Dividends Paid -2096.96 -1690.76 -1527.69 -965.385 -782.875
Issuance (Retirement) of Stock, Net -14.211 -263.512 0 1122.79 -83.433
Issuance (Retirement) of Debt, Net -135.239 -222.167 76.679 -112.153 -782.598
Foreign Exchange Effects 14.136 -2.444 2.101 1.455 3.014
Net Change in Cash -1058.86 1800.25 3141.22 -217.377 19.049
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Cash From Operating Activities 7627.06 4257.13
Cash Interest Paid 13.451 9.722
Changes in Working Capital 7627.06 4257.13
Cash From Investing Activities -6795.98 -5703.2
Capital Expenditures -2722.69 -970.212
Other Investing Cash Flow Items, Total -4073.29 -4732.98
Cash From Financing Activities -1904.07 -758.222
Financing Cash Flow Items 342.338 1.426
Total Cash Dividends Paid -2096.96 -1019.16
Issuance (Retirement) of Debt, Net -135.239 273.728
Foreign Exchange Effects 14.136 9.592
Net Change in Cash -1058.86 -2194.69
Cash Taxes Paid
Issuance (Retirement) of Stock, Net -14.211 -14.211

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

CSPC Pharmaceutical Company profile

About CSPC Pharmaceutical Group Ltd

CSPC Pharmaceutical Group Limited is an investment holding company principally engaged in the manufacture and sales of pharmaceutical products. The Company sells its products under the brand of CSPS. The Company has four business segments: Finished Drugs, Antibiotics (intermediates and bulk drugs), Vitamin C (bulk drugs) and Caffeine and Others (bulk drugs). All these segments are engaged in the manufacture and sales of related pharmaceutical products. The finished drugs include the antibiotics, cardio-cerebrovascular drugs, diabetes drugs, neurology drugs, oncology drugs and traditional Chinese medicines. The Company is also engaged in the provision of pharmaceutical research and development services, as well as the processing of sewage and pharmaceutical by-products through its subsidiaries.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, CSPC Pharmaceutical Group Ltd revenues increased 12% to RMB27.87B. Net income increased 9% to RMB5.61B. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income was partially offset by Selling and distribution expenses increase of 11% to RMB10.44B (expense), Research and development expenses increase of 19% to RMB3.43B (expense).

Industry: Pharmaceuticals (NEC)

黃河大道路226號
SHIJIAZHUANG
HEBEI 050035
CN

Income Statement

  • Annual
  • Quarterly

News

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

Four reasons why Bitcoin is surging to record highs

Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.

10:18, 14 March 2024

China’s National People’s Congress: The markets have again been left wanting more

China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.

08:23, 8 March 2024
Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

13:14, 6 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

People also watch

US100

18,249.40 Price
-0.200% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 7.0

XRP/USD

0.62 Price
-2.140% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

Gold

2,233.43 Price
+1.740% 1D Chg, %
Long position overnight fee -0.0188%
Short position overnight fee 0.0106%
Overnight fee time 21:00 (UTC)
Spread 0.80

BTC/USD

69,751.05 Price
-1.180% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading